Consistent with clinical experience (Chinot et al., 2014; Duerinck et al., 2018; Gilbert et al., 2014; Hutterer et al., 2014), the anti-VEGF antibody B20S (a mouse analog of the clinically approved antibody drug bevacizumab) as well as tyrosine kinase inhibitors of the VEGF receptors (axitinib and sunitinib) had no therapeutic efficacy, despite the on-target effect of modestly reducing the density of the tumor vasculature. Here, VEGFA is linked to neoplasm.